Biogen high-dose Spinraza approval seen supporting long-term growth

The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc (NASDAQ:BIIB, XETRA:IDP) for spinal muscular atrophy (SMA), a move analysts at Jefferies say could help sustain the company’s long-standing position in the rare disease market. According to the analysts, the decision was largely anticipated by investors despite earlier regulatory delays tied to manufacturing issues described as “benign.” The newly approved regimen, often referred to as high-dose ...